Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
cefuroxime plus erythromycin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Arm 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| cefuroxime plus erythromycin | DRUG | intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens |
| azithromycin (Zithromax) | DRUG | intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days |
| cefuroxime | DRUG | intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days |
Inclusion Criteria: Inclusion Criteria: * Patients hospitalized with a diagnosis of community acquired pneumonia (CAP) as defined by the presence of new infiltrate(s) including manifestation of consolidation, patchy, diffuse or interstitial inflammation on chest X-ray with or without pleural effus...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 1 | PHASE3 | Tozorakimab |
| GSK plc Sponsored ADR | GSK | 3 | PHASE1 | Pn-MAPS30plus, PCV20 |
| Pfizer Inc. | PFE | 4 | - | Undisclosed |
| Sanofi SA Sponsored ADR | SNY | 1 | - | Undisclosed |
| Gilead Sciences, Inc. | GILD | 1 | - | Undisclosed |
| Grace Therapeutics, Inc. | GRCE | 1 | N/A | Undisclosed |
Cefuroxime plus erythromycin is an investigational combination of two small-molecule antibiotics being studied for the treatment of pneumonia in hospitalized patients. It is being developed by Pfizer, Inc. (NYSE: PFE) and has completed a Phase 3 clinical trial in China.
Cefuroxime plus erythromycin is being developed by Pfizer, Inc., which is publicly traded under the ticker symbol PFE on the New York Stock Exchange. The combination is intended for the treatment of pneumonia and has been evaluated in a Phase 3 clinical trial.
Cefuroxime plus erythromycin is in Phase 3 clinical development. It is an investigational combination therapy and has not been approved by regulatory authorities. A Phase 3 trial for the treatment of pneumonia has been completed, but the drug remains under clinical investigation.
Cefuroxime plus erythromycin has one completed Phase 3 clinical trial, registered as NCT00648726. This open, prospective, randomized, multicenter study evaluated the efficacy and safety of intravenous followed by oral azithromycin versus cefuroxime alone or with oral erythromycin in 139 Chinese patients hospitalized for pneumonia.
Cefuroxime plus erythromycin is a combination of cefuroxime and erythromycin, two antibiotics. It is distinct from cefuroxime alone, which was used as a comparator in the Phase 3 trial NCT00648726. The combination was studied to determine if adding erythromycin improves outcomes in hospitalized pneumonia patients.